J. E. Rodriguez
9 Papers
J. E. Rodriguez is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 4 publications.
Chat about Author
Papers
Exploring clonal hematopoiesis and its impact on aging, cancer, and patient care.
J. E. Rodriguez,J. Micol,Capucine Baldini +2 more
1
Comprehensive molecular landscape of anal squamous cell carcinoma: analysis of tissue and liquid biopsies from 1844 patients
Cristina Smolenschi,Saumya D. Sisoudiya,A. Hollebecque,Smruthy Sivakumar,Meagan Montesion,Victor Euzen,V. Boige,Alice Boilève,Marine Valery,I. Sourouille,A. Bayle,Mihaela Aldea,J. E. Rodriguez,Massimiliano Gelli,Filippo Dall'Olio,A. Tarabay,T. Pudlarz,Ratislav Bahleda,Alina Fuerea,L. Benhaim,E. F. de Sevilla,M. Bani,P. Dartigues,Simon Pernot,Gautier Boillet,Kristi Beshiri,C. Massard,Luc Friboulet,Francesco Facchinetti,Ludovic Lacroix,E. Rouleau,Fabrice Barlesi,M. Ducreux,A. Italiano,Radwa Sharaf,D. Vasseur +35 more
TL;DR: This study of 1844 anal squamous cell carcinoma patients defines the genomic landscape, identifies actionable targets, and highlights the clinical value of liquid biopsy in guiding personalized therapy, particularly in HPV-driven cancers.
Clonal hematopoiesis (CH) associated mutations in patients with advanced solid tumors enrolled in phase I clinical trials.
J. E. Rodriguez,A. Bayle,Arnaud Pagès,François-Xavier Danlos,D. Le Vasseur,Etienne Rouleau,Ludovic Lacroix,B. Alonso de Castro,Vincent Goldschmidt,L. Seknazi,Antoine Hollebecque,Jean Michon,Stéphane Champiat,Aurélien Marabelle,Kaïssa Ouali,Christophe Marzac,Santiago Ponce Aix,Antoine Italiano,Jean-Baptiste Micol,Capucine Baldini +19 more
TL;DR: In this article , an increased number of CH associated mutations has been identified in patients (pts) with solid tumors, and their impact on patients' outcomes remains unclear, however, the authors aim to integrate molecular data and clinical characteristics of CH in pts enrolled in clinical trials.
Frailty IO: Frailty parameters and incidence of immune related adverse events in older patients treated with immune checkpoint blockers (ICB).
Capucine Baldini,Bérengère Beauplet,L. Seknazi,Arnaud Pagès,S. Estivin,Vincent Goldschmidt,Maxime Frelaut,S. Guitteny,Rachid Mahmoudi,Coline Montegut,J. E. Rodriguez,Anne-Laure Couderc,Elena Paillaud,Florence Canoui-Poitrine +13 more
TL;DR: In this paper , the impact of frailties on immune related adverse events (irAEs) in a real-life population of older patients treated with immune checkpoint blockers (ICB) was investigated.
Abstract A027: Clonal hematopoiesis of indeterminate potential (CHIP) in patients with advanced NSCLC treated with immune checkpoint blockers (ICB) as monotherapy: Analysis of the PREMIS study. [R]
J. E. Rodriguez,Capucine Baldini,François-Xavier Danlos,Aurélien Marabelle,Maxime Frelaut,Marco Tagliamento,Mihaela Aldea,Benjamin Besse,Jean-Baptiste Micol,Christophe Marzac,Nathalie Chaput,Christophe Massard +11 more
TL;DR: Rodriguez et al. as mentioned in this paper performed a Next-Generation Sequencing (NGS) with a panel of 74-genes dedicated to hematological alteration on DNA extracted from whole blood collected before the first administration of an ICB, within the PREMIS trial (NCT03984318).